KeyBank National Association’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.33M Sell
36,763
-1,954
-5% -$164K 0.01% 378
2026
Q1
$3.1M Buy
38,717
+4,809
+14% +$396K 0.01% 373
2025
Q4
$2.89M Sell
33,908
-1,807
-5% -$148K 0.01% 374
2025
Q3
$2.78M Sell
35,715
-457
-1% -$35.7K 0.01% 381
2025
Q2
$2.83M Buy
36,172
+233
+0.6% +$17.4K 0.01% 374
2025
Q1
$2.6M Sell
35,939
-6,934
-16% -$496K 0.01% 387
2024
Q4
$3.17M Sell
42,873
-1,354
-3% -$94.8K 0.01% 351
2024
Q3
$2.92M Sell
44,227
-2,138
-5% -$155K 0.01% 362
2024
Q2
$4.28M Sell
46,365
-2,434
-5% -$216K 0.02% 298
2024
Q1
$4.66M Buy
48,799
+4,820
+11% +$405K 0.02% 289
2023
Q4
$3.35M Sell
43,979
-1,417
-3% -$98.6K 0.01% 325
2023
Q3
$3.15M Sell
45,396
-5,667
-11% -$455K 0.02% 316
2023
Q2
$4.82M Buy
51,063
+4,835
+10% +$420K 0.02% 272
2023
Q1
$3.82M Buy
46,228
+7,344
+19% +$577K 0.02% 299
2022
Q4
$2.9M Sell
38,884
-3,825
-9% -$295K 0.01% 325
2022
Q3
$3.53M Sell
42,709
-1,972
-4% -$190K 0.02% 290
2022
Q2
$4.25M Buy
44,681
+779
+2% +$80.6K 0.02% 276
2022
Q1
$5.17M Sell
43,902
-2,271
-5% -$255K 0.02% 266
2021
Q4
$5.98M Buy
46,173
+1,483
+3% +$173K 0.02% 264
2021
Q3
$5.06M Sell
44,690
-7,821
-15% -$893K 0.02% 265
2021
Q2
$5.44M Sell
52,511
-5,756
-10% -$543K 0.02% 262
2021
Q1
$4.87M Sell
58,267
-1,089
-2% -$92.1K 0.02% 269
2020
Q4
$5.42M Sell
59,356
-1,029
-2% -$85.4K 0.03% 255
2020
Q3
$4.82M Buy
60,385
+4,667
+8% +$364K 0.03% 254
2020
Q2
$3.85M Buy
55,718
+8
+0% +$569 0.02% 271
2020
Q1
$3.5M Sell
55,710
-2,073
-4% -$149K 0.02% 268
2019
Q4
$4.49M Buy
57,783
+1,368
+2% +$107K 0.02% 275
2019
Q3
$4.13M Sell
56,415
-3,045
-5% -$214K 0.02% 282
2019
Q2
$3.66M Sell
59,460
-3,813
-6% -$231K 0.02% 293
2019
Q1
$4.04M Buy
63,273
+2,202
+4% +$126K 0.02% 279
2018
Q4
$3.12M Sell
61,071
-26,046
-30% -$1.32M 0.02% 288
2018
Q3
$5.06M Buy
87,117
+8,697
+11% +$425K 0.03% 259
2018
Q2
$3.81M Buy
78,420
+396
+0.5% +$18.5K 0.02% 279
2018
Q1
$3.63M Buy
78,024
+1,593
+2% +$69.2K 0.02% 282
2017
Q4
$2.87M Sell
76,431
-26,400
-26% -$969K 0.02% 298
2017
Q3
$3.75M Buy
102,831
+8,361
+9% +$319K 0.02% 277
2017
Q2
$3.72M Sell
94,470
-28,734
-23% -$1.05M 0.02% 272
2017
Q1
$3.86M Buy
123,204
+55,755
+83% +$1.75M 0.02% 276
2016
Q4
$2.11M Sell
67,449
-27,144
-29% -$879K 0.01% 354
2016
Q3
$3.8M Buy
94,593
+22,593
+31% +$851K 0.02% 281
2016
Q2
$2.39M Buy
72,000
+9,225
+15% +$316K 0.02% 317
2016
Q1
$1.85M Sell
62,775
-18,978
-23% -$524K 0.01% 358
2015
Q4
$2.15M Sell
81,753
-13,869
-15% -$360K 0.01% 344
2015
Q3
$2.27M Buy
95,622
+21,090
+28% +$509K 0.02% 340
2015
Q2
$1.77M Sell
74,532
-930
-1% -$21K 0.01% 424
2015
Q1
$1.79M Buy
75,462
+45,858
+155% +$1.03M 0.01% 434
2014
Q4
$628K Buy
29,604
+216
+0.7% +$4.34K ﹤0.01% 778
2014
Q3
$500K Buy
29,388
+14,568
+98% +$230K ﹤0.01% 868
2014
Q2
$212K Buy
+14,820
New +$201K ﹤0.01% 1195
2014
Q1
Sell
-18,804
Closed -$206K 1272
2013
Q4
$206K Buy
+18,804
New +$212K ﹤0.01% 1190
2013
Q3
Sell
-30,732
Closed -$344K 1267
2013
Q2
$344K Buy
+30,732
New +$364K ﹤0.01% 1094

Other funds holding EW

KeyBank National Association's EW Position: Q2 2026 in Review

KeyBank National Association reduced its Edwards Lifesciences (EW) stake by 5% in Q2 2026, selling an estimated $164K and leaving 36,763 shares worth $3.33M. The position accounts for 0.01% of the portfolio, ranked #378.

KeyBank National Association first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.98M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • KeyBank National Association held 36,763 shares of Edwards Lifesciences worth $3.33M as of Q2 2026.
  • KeyBank National Association sold 1,954 Edwards Lifesciences shares in Q2 2026, an estimated $164K.
  • Edwards Lifesciences made up 0.01% of KeyBank National Association's portfolio in Q2 2026, its #378 holding.
  • KeyBank National Association first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • KeyBank National Association's Edwards Lifesciences position peaked at $5.98M in Q4 2021.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.